title: A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody.
authors.forename: A
authors.initials: A
authors.lastname: Renkl
authors.forename: M
authors.initials: M
authors.lastname: Mockenhaupt
authors.forename: K
authors.initials: K
authors.lastname: Technau
authors.forename: Y
authors.initials: Y
authors.lastname: Herouy
authors.forename: J
authors.initials: J
authors.lastname: Norgauer
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001379:Azathioprine / Q000627:therapeutic use; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008875:Middle Aged; D010392:Pemphigus / Q000188:drug therapy* / Q000276:immunology; D011239:Prednisolone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011239:Prednisolone; D000077561:Daclizumab; D001379:Azathioprine